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Introduction
The deficiency of adenosine deaminase type 2 (DADA2) is
a recessively inherited condition caused by mutations in
CECR1. Patients present with recurrent fevers and evidence
of vasculitis/vasculopathy, including livedo racemosa, lacu-
nar strokes, polyarteritis nodosa, endothelialization of the
hepatic sinusoids with portal hypertension, and active coli-
tis. There is no recombinant form of ADA2 and thus we
attempted a) exogenous replacement of ADA2 via fresh
frozen plasma (FFP) and b) suppression of the inflamma-
tory response using anti-tumor necrosis factor (anti-TNF)
therapy. This abstract documents 22 months of clinical
treatment in the NIH DADA2 cohort.
Objectives
a) To determine if FFP infusion is safe and if it would
result in sustainable increased ADA2 levels; b) assess
clinical and laboratory response to anti-TNF agents.
Patients and methods
FFP safety and pharmacokinetics: To assess the safety
of FFP infusion, 3 DADA2 patients were admitted to
the NIH Clinical Center for 5 consecutive days of FFP
infusions. Serial ADA2 levels were drawn and FFP
volumes were increased, barring adverse effects, each
day. Subsequently, the patients were re-admitted and
administered a single 100 mL FFP dose. Blood samples
were drawn for ADA2 analysis.
Anti-TNF therapy: After comprehensive evaluation,
patients were started on anti-TNF therapy. Patients under-
went follow-up evaluation after approximately one year on
treatment. Follow-up procedures were completed as
needed.
Results
Pharmacokinetic results: Utilizing the observed increase
in ADA2 levels in patients from the pre- and post-infusion
samples over the 5 days of FFP infusions, a volume of
distribution for ADA2 of approximately 1100 ml (range:
605-2207 ml) was calculated. When serial ADA2 sampling
was conducted in the subsequent admission, the median
terminal half-life was approximately 6.4 hours (range:
4.95-8.95 hours).
Anti-TNF results: 12 patients were treated with anti-
TNF agents. The median time on therapy was 10 months
(IQR: 8.5-19). There were no significant new disease com-
plications (strokes, GI ischemia, worsening portal hyper-
tension). Inflammatory markers stabilized in all cases and
anemia improved. One patient with documented portal
hypertension and esophageal varices had variceal resolu-
tion after 12 months of therapy. The cutaneous PAN
lesions improved but there was persistent livedo racemosa.
Conclusion
Although the administration of FFP caused a transient
increase in serum ADA2 levels, the short half-life would
necessitate that large volume infusions (>200-300 ml) be
given at least daily, rendering this treatment unfeasible.
There has been dramatic clinical and laboratory improve-
ment on anti-TNF agents.
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